Celiac Disease Patients Following Recommendations of ESPGHAN, HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes
Conditions
Keywords
Celiac disease, HLA-DQ2.2, HLA-DQ2.5, HLA-DR7-DQ2, HLA-DR3-DQ2
Brief summary
Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.
Interventions
Sponsors
Corporacion Parc Tauli
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of celiac disease following ESPGHAN recommendations * HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes
Exclusion criteria
* Patients who have not been diagnosed for celiac disease * HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-tissue transglutaminase | Up to 1 month after diagnosis |
Secondary
| Measure | Time frame |
|---|---|
| Anti-Endomysium autoantibodies | Up to 1 month after diagnosis |
Other
| Measure | Time frame | Description |
|---|---|---|
| Oberhuber histological damage classification | Up to 1 month after diagnosis | — |
| Clinical characteristics of celiac disease | Up to 1 month after diagnosis | Asymptomatic, intestinal symptoms, extra-intestinal symptoms, European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) score |
Countries
Spain
Outcome results
None listed